Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.88 USD
Change Today +0.57 / 2.95%
Volume 785.8K
MNTA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Open
$19.37
Previous Close
$19.31
Day High
$19.91
Day Low
$19.08
52 Week High
05/11/15 - $20.75
52 Week Low
10/13/14 - $9.38
Market Cap
1.3B
Average Volume 10 Days
1.2M
EPS TTM
$-1.78
Shares Outstanding
64.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOMENTA PHARMACEUTICALS INC (MNTA)

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug consisting of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 2 clinical study derived from heparin; hsIVIg program, a hyper-sialylated version of intravenous immunoglobulin; SIF3 program, a novel recombinant protein containing three IgG Fc regions joined to maximize activity; and Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

256 Employees
Last Reported Date: 02/27/15
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $643.4K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $400.7K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $374.8K
Senior Vice President and President of Biosim...
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM

Momenta Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Richard P. Shea, Chief Financial Officer, Senior Vice President and Treasurer.

Momenta Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for the Second Quarter and Full Year 2015

Momenta Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported a net loss of $21.9 million, or $0.40 per share, compared to a net loss of $27.4 million, or $0.53 per share for the same period in 2014. Total revenues were $8.6 million compared to $10.8 million for the same period in 2014. Operating loss was $20.08 million compared to $27.62 million for the same period in 2014. The company provided guidance that its net cash usage, excluding revenue from the approval and potential launch of Glatopa, and excluding revenue from any potential new collaboration(s), will be approximately $28 to $32 million per quarter for 2015. The projected cash burn for the second quarter will be offset by a $10.0 million milestone earned for the sole approval of M356 under the Sandoz collaboration. In the quarter that Glatopa is launched, the Company will also earn an additional $10.0 million milestone from Sandoz.

Momenta Pharmaceuticals Inc. Presents Key Glatopa(TM) (Glatiramer Acetate Injection) Data at American Academy of Neurology Annual Meeting

Momenta Pharmaceuticals Inc. presented new data from studies conducted as part of the ANDA submission for once daily Glatopa (glatiramer acetate injection) at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. The posters presented provide examples of a selection of methods the company utilized to show the equivalence of Glatopa and once daily COPAXONE 20 mg. Presentation highlights: Poster #P1.144 – Comparative Gene Expression Profiling between a Generic (Glatopa) and Brand COPAXONE (glatiramer acetate injection): Microarray analysis across the entire genome was performed in murine glatiramer acetate-responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. Multiple statistical methods consistently demonstrated assay sensitivity as well as equivalent gene expression profiles between Glatopa and Copaxone. Poster #P1.145 – Demonstration of Equivalence between a Generic (Glatopa) and Brand COPAXONE (glatiramer acetate injection): This poster summarized company's overall approach of comparison, as well as multiple examples of equivalence of starting materials and basic chemistry; equivalence of structural manufacturing process signatures; equivalence of physicochemical (structural) properties; and equivalence of biological/immunological (functional) properties. The selected assays and data presented at AAN are examples of the physicochemical methods and biological/immunological assays that were submitted to the FDA as part of the recently approved data package for Glatopa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $19.88 USD +0.57

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $1.92 USD 0.00
Natco Pharma Ltd 2,282 INR -13.30
OraSure Technologies Inc $6.60 USD +0.18
SciClone Pharmaceuticals Inc $9.44 USD +0.14
Sucampo Pharmaceuticals Inc $15.85 USD -0.08
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.0x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit www.momentapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.